ArticleBiomarkers in medicine2024
TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China.
Article in Biomarkers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling the prognostic and immunotherapeutic role of Tregs in lung cancer using integrated analysis of single-cell and bulk RNA-sequencing.Oncology letters · 2026Article
- Molecular and clonal evolution of primary lesionsTranslational lung cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsStudy on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients. MATERIALS AND
methodsA retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed.
resultsThe superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (
conclusionXuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.